Detalhe da pesquisa
1.
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.
N Engl J Med
; 366(6): 520-9, 2012 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-22149876
2.
Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 346-7, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24674873
3.
Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.
Oncologist
; 19(4): 348-9, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24674874
4.
Everolimus plus exemestane as first-line therapy in HRâº, HER2â» advanced breast cancer in BOLERO-2.
Breast Cancer Res Treat
; 143(3): 459-67, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24362951
5.
Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.
Cancer
; 119(10): 1908-15, 2013 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23504821
6.
A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma.
Diagnostics (Basel)
; 12(2)2022 Feb 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35204627
7.
Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions.
Drugs
; 66(12): 1577-91, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-16956305
8.
Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer.
PLoS One
; 11(7): e0154009, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27454930
9.
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.
J Clin Oncol
; 34(5): 419-26, 2016 Feb 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26503204
10.
Maintenance of differentiation capacity of HT-29 cells after radiation exposure.
Int J Radiat Biol
; 81(3): 211-20, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16019930
11.
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Eur J Cancer
; 48(4): 465-74, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22285181
12.
AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51.
Cancer Res
; 68(22): 9404-12, 2008 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19010915
13.
Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
Arch Gynecol Obstet
; 278(5): 457-62, 2008 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-18273626
14.
Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.
Oncologist
; 12(3): 253-70, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17405890